SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS ARTICLE M impact

Protagonist Therapeutics Reports $220.0M Q3 2026 Net Income

Protagonist reported Q3 2026 revenue of $274.4 million, versus $4.7 million in Q3 2025, and net income of $220.0 million, compared with a $39.3 million net loss. Cash, cash equivalents and marketable securities totaled $834.6 million at September 30, 2026, versus $646.0 million at December 31, 2025.

PTGX

Protagonist reported Q3 2026 revenue of $274.4M versus $4.7M in Q3 2025, and net income of $220.0M versus a $39.3M net loss. Cash, cash equivalents and marketable securities totaled $834.6M at September 30, 2026, versus $646.0M at December 31, 2025.Material DetailsContext by AI AnalystThis is a maj…

Related stories